Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）
摘要
NCT02098837 and EudraCT 2013-003704-39.
更多查看译文
关键词
dolutegravir,switch,weight
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要